Skip to main content

Parabilis Medicines, Inc Investor Event Transcript, Nov 9, 2026

Parabilis Medicines, Inc. (PBLS)

Parabolus plans to initiate the global pedestal Phase Three study of Zolucatetide in the first half next year, following an FDA-agreed induction-maintenance regimen; desmoid data showed 62% ORR at 24 months and 72% ORR at 32 weeks. AI summary

Investor Event Transcript 2026-11-09 For: 2026-12-31
Added on November 09, 2026

Conference Transcript - PBLS 2026-11-09

Michael Schmidt, Host

All right. Welcome to this next Fireside Chat. My name is Michael Schmidt. It's my great pleasure to welcome Matai Mamon, the CEO of Parabolus. Matai, welcome. Thanks for joining us.

Matai Maiman, CEO

Pleasure to be here.

Michael Schmidt, Host

So big picture question to lead in. So for investors who are getting still to know the Parabolus story, what is the core idea behind the Helicon platform and what does it enable you to do?

Matai Maiman, CEO

Yeah, so thanks for that question. Parabalus is on a journey to do something, I think, pretty unique in our ecosystem, where we've developed a platform that is called the Helicon platform. It's a special kind of peptide-related platform that allows us to access proteins inside cells that don't have traditional pockets. They don't have traditional binding cavities. So that turns out to be about 80% of proteins inside cells. So using that technology that's been developed first at Harvard for about 15 years and then starting at Parabolis about 10 years ago, it's been in development for about 25 years. And I'd say at this point, it's fully reduced to practice and it's working phenomenally well. And I think we're alone at the moment doing that.

Michael Schmidt, Host

Great. And so your lead program, Zolucatetide, targets beta-catenin. First of all, maybe why beta-catenin? What makes this target so interesting?

Matai Maiman, CEO

Yep. So the Wnt beta-catenin pathway has been on the table as having a close causal association with cancers since Burt Vogelstein published in 1990. So this is a well-known pathway. And most every pharma, including myself when I was at Merck and J&J, had a go at the key node, which is beta-catenin and TCF, but have all come up empty. And so using Parabolus' proprietary platform, we've been able to make a very, very strong, potent, selective, competitive, reversible inhibitor of exactly the interaction that everyone's wanted for a long time.

Michael Schmidt, Host

And so there's obviously a number of opportunities or indications where beta-catenin and the pathways implicated. So how did you decide to prioritize opportunities to pursue?

Matai Maiman, CEO

Yeah, excellent question. I think for us and for maybe in oncology in general, there's certain indications where if you're sitting on a mechanism like beta-catenin-TCF, so leucatatide, there are certain indications that are the best test beds and represent substantial unmet need because testing is likely unnecessary because the population is homogeneously driven by the particular pathway that you're We're trying to modulate, and that's the case for us with desmoid tumors, FAP, adenominus craniofaryngioma, ACP. Those three, and there's potentially more than that, are homogeneously driven by either beta-catenin or APC mutations, so they made a lot of sense. There's a whole suite of indications that are rare and also homogeneous and less rare and less homogeneous, like hepatocellular and colorectal, that are right there waiting for us to complete our first wave.

Michael Schmidt, Host

Okay. And so most of the phase one data so far has been generated in desmoid tumors. Just to remind us, and again, you had an update recently at ESMO as well. So remind us, what have you learned from the desmoid tumor or the phase one study more broadly so far? And what gives you confidence heading into this next step, which is a phase three study?

Matai Maiman, CEO

Yeah. So first of all, we've gotten to know the Desmoid community particularly well through the foundations, the patients, the patient journey, the plight of these poor patients. They're phenomenally painful or debilitating tumors that really have no great therapies today. There are gamma-sacretase inhibitors that are ones approved and ones coming that have been approved for treatment, but they're not optimal with respect to either efficacy or safety tolerability. So what we see right now is we've been able to dose our Zolocatatide, our beta-catenin-TCF inhibitor, in a manner where we see highly differentiated efficacy and highly differentiated safety tolerability, offering these patients something that's far more definitive for their illness than has been available to them in the past. So we're feeling really good. So, you know, the achievement of getting Zolacatetide was a big deal, but the achievement now of having dose 76-plus patients now and having a very nice induction maintenance dose selected agreed with FDA that maximizes efficacy and minimizes any safety tolerability and creates this well-tolerated medicine. And that's a second great achievement. Because sitting here three, four years ago, that was not like evident, self-evident that that would be achievable. So we're very proud of that going into the phase three study that we're calling pedestal. And we're still committed to initiating that study in the first half next year.

Michael Schmidt, Host

And maybe just going back to the ESMO data, so what did you learn from this update, especially as it pertains to how activity could pan out over time, since it was still a very early look at the data?

Matai Maiman, CEO

So there are three learnings since the S1 published in June of this year that are new learnings. One is that we have agreed a dose and schedule regimen with FDA. That's a big deal. And that was the result of a very carefully constructed dose optimization study with three arms looking at induction maintenance. So, that's number one and very important because now that enables us to take the next step forward, of course, with a global registrational study. So, we're looking to have this product approved globally. Second, we've more than doubled the safety database, and it's a novel mechanism, and we've gone from a fairly large database to twice or more that database with this update, and we've seen no new issues at all, and it continues to be well-tolerated, well-managed safety profile. And third, we've more modestly increased the amount of efficacy data that we've seen looking at extensions beyond what we were able to cut in February, which was the June disclosure, to now, where we continue to see just incredibly good efficacy. So we were able to report at 24 months a 62% ORR, and at 32 weeks, we were able to see a 72% ORR. So generally speaking, patients come on this product, Zolucatotide, and generally speaking, they all move downward in their tumor volumes and tumor diameters. So all the symptoms, all the discomfort, all the debilitation that comes from having desmoid tumors is because these tumors have mass that push into adjacent tissue. So it could push into like your trachea and deviate it and keep you from breathing. It could push into your chest wall and cause just exquisite pain. It could push into your joints and keep you from walking or moving limbs. And so we're thrilled to see what we're doing for patients as we shrink these tumors relatively uniformly and with with time ever more deeply.

Michael Schmidt, Host

Okay. So perhaps walk us through the path to approval and the design of the pedestal study.

Matai Maiman, CEO

Yeah. So the pedestal study, the good news is it's exactly like the prior registrational studies that have been run before. So we're not taking any regulatory risk here. So we have a PFS endpoint, a progression-free We will measure, that's our primary. We will measure, of course, longest diameter. This is the resist endpoint. And we will measure volumes. We will measure different symptomology through PROs. And we'll measure other aspects that are going to be important to the patient. So these are all typical of other studies. We'll enroll this study so that the patients have documented growing tumors. So they must have grown 20% in the past year. Interestingly, and for the first time ever in any study, we'll have probably a bit more than half of these patients have failed on a gamma secretase inhibitor. So prior to this, no studies enrolled such patients. So they will have either had progressive disease or they will have been intolerant to niragastastat or varagastastat prior to entering our study. We have, and maybe you will ask this question, but we had about 70% such patients on our study to date, and we see no differences in efficacy, safety, regardless of treatment history here, including with gamma-sacritase inhibitor.

Michael Schmidt, Host

Yeah. So one question we hear a lot from investors, obviously, how could solucalitide fit into the market where you have an oral approved, a second one potentially coming in soon? And what are the opportunities that the product could capture in Desmoid?

Matai Maiman, CEO

Yeah, so a couple points to make there. We see lots of patients now sign up for our study that would never take a gamma-striketase inhibitor. They've chosen not to. Why would they not? Yes, there's diarrhea, rash, that you have sometimes grade 3 levels, while you sit and wait for efficacy that may never come. So even after, you know, 32 weeks, you have maybe a third of these patients have responses to a gamma-secretase inhibitor. That's a long time to wait with these symptoms. Perhaps most importantly, though, the majority of desmoid patients are women. And one of the strong safety tolerability problems with gamma-secretase inhibitors, with notch modulators, is ovarian dysfunction. And there's been data that can be long-lived. So that also is another factor that bothers the majority of the population. So we see patients right now enter the study that would never take a gamma-striketase inhibitor, and others enter right now that have failed. So those second group have no options. So we have long queues at both the site level and the overall trial level for patients accessing the trial, even before phase three. So I see when you offer a product like this that has great efficacy, well-managed, very good tolerability for exquisite unmet needs, you get people coming.

Michael Schmidt, Host

Yeah, makes sense. And then, you know, we get asked this, obviously, the formulation so far is IV every two weeks, I believe, and then with a different maintenance regimen. But how do you think that could work out from a practicality perspective relative to or else?

Matai Maiman, CEO

Yeah, so the game plan here for us is we will do this phase three intravenously. And by the way, all the patient attractiveness to the study is with the IV formulation. So despite that, you see a lot of patients striving to get into our study. That said, we are actively working on a convenient at-home auto-injector device that one can self-administer, and so the idea is to do a bioequivalence study sometime during the course of phase three. Everything we have right now implies all the data, the PKPD, PK efficacy, PK safety data, imply an area under the curve, an exposure-related effect in our modeling. So we would go for exposure equivalents with the subcutaneous or our self-administered product, such that we can launch with a self-administered product. But I just want to emphasize that even with the IV, there's long queues of patients looking to get into our study.

Michael Schmidt, Host

Okay, great. So, what are the next updates going to be in Desmond?

Matai Maiman, CEO

So, the next big step for us is to begin the pedestal study. This is the first global registrational study for our company, and so we have an outstanding team that we've recently hired that are preparing to launch the study globally, so globally, including in Asia, Europe, and the United States, Canada. So, that's a very exciting Next step. We haven't committed to exactly when we would provide the next data update, but we'll have close to 100 patients prior to the Phase III study that now have been dosed, and we'll continue to watch them as single arm, and we'll be able to report out. So from an investor standpoint, that's a good thing because we'll have all this data like maturing over the next two plus years while we wait for a phase three data card to flip, which wouldn't be nearly as mysterious as if you had none of this data. So that's a positive from an investor standpoint.

Michael Schmidt, Host

Some more updates coming there. Okay, so FAP, another big opportunity. We've had a lot of investor discussions about that potential market. There are really no FDA approved drugs, as far as I'm aware. So maybe how would you describe FAP as an opportunity? And again, why does gamma secretase inhibition make sense here?

Matai Maiman, CEO

Yeah. So as with desmoid, where the 90% driver in desmoid is beta-catenin, 10% is APC, 100% of FAP is driven by APC mutations. It is a germline mutation. It's an inherited disease. You're born with every cell in your body having an APC mutation. This is a bad disease to be born with, a bad genetic condition to have at birth. The principal manifestation is in your gut where you develop these polyps. So the polyps just start showing up. Typically, when you're a young person, maybe 13, 14, 15 years old, you start getting polyps. If you happen to know you have FAP, then gastroenterologists, pediatric GI folks can do colonoscopies, endoscopies, to look in your GI tract and try to excise these polyps. But that typically or always becomes an impossible task as these polyps are growing in number, and you get dozens, hundreds, even thousands of polyps, And you can no longer be certain as a physician that you're excising the bad ones. And so what we've seen so far is pretty phenomenal data. So we've only disclosed two patients to date in the S1, but in both of them, there were these dramatic reductions in polyps. If you ask us, it's not shocking that this be the case because there's not much going on in these polyps except for the APC mutation that you're born with and the second hit of So that's what we've seen. We've replicated that in preclinical studies. And the very interesting thing, Michael, that we're doing right now is we're piggybacking on our desmoid study, because 10% of all desmoid patients have APC mutations and are FAP patients. So we've been able to collect as bonus data, FAP data through endoscopies. These are typically post-colectomy patients. We have a dozen plus patients right now that we have in our trial that we are striving to get endoscopies on. It's a desmoid study, so it's not the case that we can demand when they come in, but some of them are coming in, and we hope to be able to disclose that data in Q1 next year so that we'll have more than just the two patients we have right now. In addition, we've just announced that we've initiated, because in our minds, we have proof of concept right now, and we're very excited by the condition, treating this condition. We've initiated quite a robust dose and dose regimen finding study so that we know exactly how to dose. We will know at the end of that exactly how to dose solucatatide. That one is a normal study. So we'll have, you know, pre and post and three months, six months scopes, and we'll expect that data, you know, next year. We don't know exactly when, but it likely will not comprise, that study will not have patients in the Q1 update. It'll be through later next year.

Michael Schmidt, Host

And so as you mentioned, you did have these two interesting case studies reported already. So how much additional data will you have in this 1Q update?

Matai Maiman, CEO

Yeah, good question. We have 12 patients that we've dosed. I don't know that we'll probably have, I would guess, the majority. We're still waiting for scopes, right? But if I'm anticipating, it'll be the majority of those, but it might not be the large majority. So don't know. And as a caution, we don't have hard counts on the pre, but we have hard counts on the post-zolucatatide. So baseline will be more qualitative, but if we continue to see the kind of data that we've already reported, the two prior patients were so dramatic, you don't need the pre to understand you've done something phenomenal for these patients.

Michael Schmidt, Host

And then maybe thinking ahead, if you have a drug that works for this condition, what are possible development opportunities? So you mentioned patients get a colectomy in some cases or in most cases. What are possible paths to market for this condition?

Matai Maiman, CEO

Yeah, that's a great question. So there is one program right now that's in phase three. It's a company called Biodexa with an oral formulation of rapamycin called E-Rapa, and they have what presumably is an agreed program with FDA to run a placebo-controlled study looking at a variety of endpoints, including Spiegelman's, which is both the polyp burden of these patients, And the histological features of these patients, plus, of course, heart outcomes like diagnosis of cancer or surgeries, major surgeries like Whipple procedures. These are for post-colectomy patients that that endpoint is constructed. So that's out there as a possibility of running an outcome study. We would say, however, just medically, that in such situations where you've reduced 20%, 30% of polyps, you can't be entirely sure whether you've done something meaningful for these patients. Just as a physician, you can't be sure. So it's not unreasonable to demand some sort of outcome. If you've so dramatically eliminated polyps or left about a handful that you can then excise, your certainty medically goes up. So we remain hopeful and just open that we have a range of possibilities open to us. And at the right moment in 2027, we will take a critical mass of data to regulators, including FDA, to talk to them about possibilities.

Michael Schmidt, Host

Great. Okay, and then the third, sort of, One concentrated, beta-catenin pathway-driven concentrated opportunities is ACP, which is a rare brain condition. So, yeah, maybe talk about that opportunity and how the program could fit in there.

Matai Maiman, CEO

That's one where we're particularly interested, and the physician community is, I would say, very excited by the data that we've been able to produce to date. What adenominus craniofringioma is, is it's a tumor that's, once again, homogeneously driven by the Wynn pathway, beta-catenin mutations, that arises from the stalk of your pituitary gland in your pituitary fossa. So it's a small area that comprises your pituitary gland behind your eyes. It's formally outside the blood-brain barrier, but abuts the blood-brain barrier. So it's a brain tumor, but sits outside the BBB. And so we've seen, we presented, actually, as an oral podium presentation at the Society of Neuro-Oncology meeting in December last year, Three very phenomenal results, where in three out of three patients, once again, not surprisingly, given the causal biology, we were able to help all three of these patients and all three tumors shrunk. And since the IPO and since having more proceeds and more capital available, we're leaning heavily into the syndication and we'll be able to provide more data first half next year. In this particular situation, And we think it might be, since the patients have no treatments whatsoever, and the patients are refractory to chemotherapy, radiation is iffy in such young patients. It's typically a disease of young people. You have nothing. And so it is quite possible here that we will seek a single arm trial to get to market. So that's something that we'll be able to talk about more in 2027.

Michael Schmidt, Host

How much additional data will you be able to present next year?

Matai Maiman, CEO

We've just started recruiting, right, since the IPO, and so there will be some more data. It won't be dramatic, but there will be some more data for us to be able to talk about.

Michael Schmidt, Host

And what are potential regulatory endpoints in this condition?

Matai Maiman, CEO

So this is a tumor, right? So it is a tumor, but it has very funny or asymmetric shapes to it. It's cystic and solid. It's got these finger-like projections, so it extends into and out of the cavity, your fossa. So it is possible to use just the longest diameter, again, resist, and we see great data using that. It's also sometimes preferable to just look at what physicians today use, and they typically use the whole of the tumor and the volume of these tumors and how much they impinge on associated the optical nerve is right there, the other brain tissue is right there, And they look at the totality of symptoms and volume of these tumors. So we'll measure it all. But we think the most straightforward, since we would win on resist, would be resist.

Michael Schmidt, Host

Okay. So in the last minute, I just wanted to ask about your two prostate cancer programs, which are preclinical still, but going into phase one soon. So just maybe help us understand how the ERC and the androgen receptor program fit into the prostate cancer landscape.

Matai Maiman, CEO

Yeah, so excellent question. We're very excited about that. I spent a lot of time in my prior role thinking about prostate cancer, and both of these, we believe, will be very meaningful additions to the treatment armamentarium. So with ERG, 40 to 50 percent of men with prostate cancer have an ERG-tempurous fusion. And so ERG is then expressed at vast quantities that colludes with the androgen receptor and drives even small amounts of androgen receptor to grow a tumor. The androgen receptor itself is a central player. And so what we've done is what the ecosystems kind of wanted to do for a long time is create an allosteric engager of androgen receptor, so separate from where all the other AR modulators bind today, including apalutamide, enzalutamide, others. And Hulda and others. So they all bind the same pocket where testosterone normally engages AR. And so we bind separately, and we only bind the on state of AR. So we would be expected to work on basically the two major resistance mechanisms, which is mutation and amplification of AR. And most importantly, we can be used in conjunction with any of the AR modulators today. So much like in HIV, the central players like reverse transcriptase were kind of dual-tackled with NNRTIs and NRTIs. We imagine doing the exact same thing for men with prostate cancer, tackle the central player, gang up on it, and hopefully help them out.

Michael Schmidt, Host

Great. And those will go into phase one, I think you said, towards the end of next year?

Matai Maiman, CEO

Yeah, we committed, we've said that INDs towards the end of next year.

Michael Schmidt, Host

Well, thank you, Matt. I appreciate it.

Matai Maiman, CEO

This was a great conversation. Thank you, Michael.